Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis

Fernández‐Peñas, Pablo; Jones‐Caballero, María; Espallardo, O.; García‐Diez, Amaro

doi:10.1111/j.1365-2133.2012.10806.x

Cited by 50 publications

(31 citation statements)

References 14 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Skindex was generated from published literature and directed‐focus sessions with patients, nurses and physicians . The Skindex has been used in different populations, ranging from those with psoriasis and acne to those with contact dermatitis, and it focuses on three domains – symptoms, emotions and functioning, with scores ranging from 0 (best) to 100 (worst). Skindex‐16 and Skindex‐29 showed evidence of responsiveness and reproducibility .…”

Section: Resultsmentioning

confidence: 99%

A systematic review of patient‐reported outcomes in patients with cutaneous lupus erythematosus

et al. 2016

View full text Add to dashboard Cite

Cutaneous lupus erythematosus (CLE) is a chronic dermatological autoimmune disease marked by photosensitive lesions that can lead to hyperpigmentation changes, scarring and hair loss. Health-related quality of life (HRQoL) in patients with CLE is severely impaired. Given the heterogeneous nature of CLE, health perceptions of patients can differ significantly from those of clinicians. It is important to use subjective measures, such as patient-reported outcomes (PROs), to capture HRQoL data in patients with CLE. We conducted a systematic review of published PRO instruments used in measuring HRQoL in patients with CLE. Also, we examined the disease burden on HRQoL in patients with CLE. To identify studies, PubMed/MEDLINE, Web of Science and CINAHL were searched using 'CLE/cutaneous lupus erythematosus' in combination with PRO-related keywords such as 'quality of life', 'self-report' and 'instrument'. English-language articles published between 2003 and 2014 were identified. A total of 482 citations were identified in the initial search. Eleven studies met our inclusion criteria, and five PRO instruments were found to be used: Skindex (versions 16 and 29), Dermatology Life Quality Index, 36-Item Short-Form Health Survey, and visual analogue scales for pain and pruritus. Patients with CLE reported having poor quality of life and experienced symptoms ranging from pain, pruritus and fatigue to photosensitivity. There is a limited number of studies examining PRO in patients with CLE. While our findings suggest that quality of life in patients with CLE is poor, further studies are needed to understand better the impact of CLE from patients' perspectives.

show abstract

Section: Resultsmentioning

confidence: 99%

A systematic review of patient‐reported outcomes in patients with cutaneous lupus erythematosus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…All five trials used either Skindex-16 or DLQI in assessing Qol. These tools have been validated in dermatology as standard assessment tools which in turn made their results plausible (52). Baseline assessment of Qol was conducted in three trials (7,26,27) however it was unclear in two (28,29).…”

Section: Discussionmentioning

confidence: 99%

Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Haruna

Lipsett

Marignol

2017

View full text Add to dashboard Cite

(OR: 0.29; p<0.0001) and reducing the mean RD score p<0.00001 Radiation induces damage to the skin, activating inflammatory pathways and causing cytokines overproduction (1, 2). Radiation dermatitis is a common acute side-effect that occurs within hours to weeks after the start of radiotherapy (3, 4) and affects more than 87% of patients (2, 5). Radiation dermatitis can limit the therapeutic dose delivered to patients and can, sometimes, lead to a break in treatment, thus potentially compromising local control and survival outcome (1, 6). It can also have a considerable impact on patients' quality of life (7,8). Despite significant development in radiotherapy techniques, efficacious interventions in the prevention of acute skin reactions is still lacking and current evidence is unable to provide adequate guidelines for the management of this sideeffect (9, 10). Studies have examined numerous topical agents such as Aloe Vera, aqueous cream, Calendula, petrolatum and sulcrafate cream as a means to reducing the dehydrating effects of radiation dermatitis (6,11,12). However, the results in terms of managing radiation dermatitis and treatment related pain have not been clinically significant (13,14). Corticosteroids have anti-inflammatory properties and are known to down-regulate cytokine gene expression, making them ideal for managing radiation dermatitis (15-17). A systematic review by Bolderston et al. concluded that there is limited evidence to support or oppose the use of topical agents for the management of acute radiation dermatitis (18).Skin care advice given to breast cancer patients varies among institutions (19). No gold-standard for the appropriate management of this side-effect exists and in most cases the decision of care is left at the discretion of the health care professional rather than clinical evidence (20,21). Clinical advice is often given based on anecdotal evidence (22).The present systematic review and meta-analysis was conducted to assess the potential efficacy of corticosteroids in the management of RD and its impact on pain and quality of life in female breast cancer patients. However, the anticipated adverse effect associated with steroids is not evaluated and is beyond the scope of this review. We restricted our review to one site only due to radiotherapy dose variations used in different sites. Materials and MethodsSearch strategy for identification of studies. The electronic literature search was conducted up to and including March 2017. The search terms used were corticosteroid, radiation dermatitis, breast cancer, management, and prevention. The reference lists of potentially eligible studies were subsequently hand searched to identify 5343

show abstract

“…In an observational, prospective study by Fernandez-Penas et al, 379 patients with mild to severe psoriasis completed the Skindex-29, 144 patients completed the DLQI, 135 patients completed the Psoriasis Disability Index (PDI), and 100 answered the Short Form 36 (SF-36) [21]. The study showed that the majority of subscales for the DLQI, the PDI, and the SF-36 had substantial floor effect, indicating these measures would have poor sensitivity responsiveness in mild to severe psoriasis.…”

Section: Skindexmentioning

confidence: 99%

Patient-Centered Outcomes in Dermatology

Okland

Armstrong

2015

Curr Derm Rep

View full text Add to dashboard Cite

Health outcomes can be captured and reported from a number of perspectives, and the patient's perspective is central to successful healthcare delivery and optimizing health outcomes. A patient-centered approach is important in dermatology. We discussed the meaning and application of "patient centeredness," "patient-centered outcome measures (PCOM), " and "patient-reported outcomes (PROs)" in dermatology. We highlighted the important roles that organizations such as the Patient-Centered Outcomes Research Institute (PCORI) and the International Dermatology Outcome Measures (IDEOM) play in advancing patient centeredness in skin diseases. We examined classic patient-reported outcome measures such as the Dermatology Life Quality Index (DLQI) and the Skindex. We also explored patient-centered outcomes in dermatologic surgery. With the development of patientcentered outcome measures, patients are able to express how their skin disease affects their lives in a systematic and valid fashion. These responses are highly valuable in guiding clinical decision-making and improving all aspects of patients' well-being.

show abstract

Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis

Abstract: Skindex-29 has better sensitivity to clinical severity with minimal floor effect, and covers the main domains explored by the other three QoL instruments in patients with mild to severe psoriasis.

Cited by 50 publications

References 14 publications

A systematic review of patient‐reported outcomes in patients with cutaneous lupus erythematosus

A systematic review of patient‐reported outcomes in patients with cutaneous lupus erythematosus

Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Patient-Centered Outcomes in Dermatology

Contact Info

Product

Resources

About